Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities (TERMGGO)
A Prospective, Multi-center, Double-blind Randomized Controlled Clinical Trial on the Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
연구 개요
상세 설명
Lung cancer is one of the most deadly malignant tumors in the world. It is estimated that 0.2-20% of lung cancer patients have multiple primary lung cancers at the time of diagnosis, and many of them present with multiple ground glass opacities. The surgical method for such multiple lesions depends on their number, anatomical location and size, as well as the age and pulmonary function of the patient. It is easily affected by the subjective judgment of the surgeon. Besides, many of these patients develop multiple lesions that cannot be resected at the same time, and there haven't been established a standard therapy for residual GGO lesions after surgery.
According to the National Comprehensive Cancer Network (NCCN) guidelines, EGFR-TKI is recommended for the adjuvant treatment of stage IB-ⅢA NSCLC with EGFR mutations. However, it is not clear whether EGFR-TKI is effective for multiple primary lung cancers or the residual GGOs after surgical resection of the EGFR mutation positive main cancers. At present, there have been retrospective studies showing that application of EGFR-TKIs targeted therapy can significantly reduce the diameter of residual GGOs after surgery resection of EGFR mutation-positive primary lesions for MPLC patients, and reduce the secondary surgery caused by the progression of the lesion. However, there is no prospective Studies confirming the efficacy and safety of EGFR-TKI on these postoperative residual GGOs lesions.
This study is a multi-center, prospective, double-blind, comparative clinical research. This study plans to enroll 138 patients with multiple primary lung cancers (cTis-T1c, N0, M0) that manifest GGO and cannot be resected at the same time, patients should have undergone surgical resection of the EGFR mutated main lesion, and have no less than 1 GGO lesion remaining after surgery. Eligible patients will be randomly divided into the treatment group (receiving furmonertinib mesilate tablets) or control group (placebo) at a ratio of 1:1. The grouping process was strictly double-blind for both the investigators and subjects. By collecting the relevant data of patients' baseline images, pathology, and follow-up images during treatment, statistical analysis is used to evaluate the effectiveness (response rate, objective remission rate), safety, and relevant influencing factors (including CTR value of the main lesion, number of residual lesions, diameter of the largest residual lesion, higher stage of the main lesion, residual lesion's density, etc.) of EGFR-TKI treatment.
This study is expected to prove that compared with the placebo in the control group, EGFR-TKI can significantly reduce the diameter of residual GGO lesions in patients with EGFR-positive multiple primary lung cancers with ground-glass density, and bring a higher objective response rate (ORR) but did not significantly increase the incidence of adverse effects.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Hecheng Li, PhD, MD
- 전화번호: +8613917113402
- 이메일: lihecheng2000@hotmail.com
연구 연락처 백업
- 이름: Yajia Zhang, PhD, MD
- 전화번호: +8613817163025
- 이메일: zhangyajieryan@163.com
연구 장소
-
-
Fujian
-
Fuzhou, Fujian, 중국
- 아직 모집하지 않음
- Fujian Medical University Union Hospital
-
연락하다:
- Chun Chen, Phd, MD
- 전화번호: 00860591-83357896
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국
- 아직 모집하지 않음
- The First Affiliated Hospital of Nanchang University
-
연락하다:
- Bentong Yu, PhD, MD
- 전화번호: 00860791-88692748
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국
- 아직 모집하지 않음
- Tangdu Hospital
-
연락하다:
- Xiaolong Yan
- 전화번호: 008602984777777
-
-
Shanghai
-
Shanghai, Shanghai, 중국, 200025
- 모병
- Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
-
연락하다:
- Yajie Zhang, PhD, MD
- 전화번호: +8613817163025
- 이메일: zhangyajieryan@163.com
-
연락하다:
- Jiahao Zhang, MD
- 전화번호: +8615821928973
- 이메일: zhangjiahao135@126.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국
- 아직 모집하지 않음
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
연락하다:
- Jian Hu, PhD, MD
- 전화번호: 00860571-87236114
-
Hangzhou, Zhejiang, 중국
- 아직 모집하지 않음
- Second Affiliated Hospital, School of Medicine, Zhejiang University
-
연락하다:
- Ming Wu, Phd, MD
- 전화번호: 00860571-87783777
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 1. The patient was diagnosed with MPLC (based on the previously published MM/ACCP clinical criteria). The preoperative chest CT scan (1mm slice thickness) found two or more ground glass lesions (≥6mm and <3 cm, pure ground glass or partial solid) that could not be operated at the same time;
- 2. The patient has received surgery to remove the main lesion. The pathology of the main lesion is NSCLC with sensitizing EGFR mutation positive (19del/L858R), with or without other EGFR mutations including T790M;
- 3. After resection of the main lesion, the patient should have at least one residual ground glass nodules (≥6mm and <3 cm) that are suspected of being malignant and cannot be resected simultaneously with main lesion. The malignancy has been confirmed by both qualified radiologist and thoracic surgeon;
- 4. The included MPLC patients' clinical staging from preoperative evaluation should be cTis-T1c, N0, M0 (according to NCCN/EEJC 2021 V1);
- 5. Patients' ECOG PS score 0-1;
- 6. The subject voluntarily participates in the study and has signed a written informed consent form.
Exclusion Criteria:
- 1. MPLC with lymph node metastasis, unresectable disease or distant metastasis, including pleural and pericardial metastasis;
- 2. Those who have severe cardiac, pulmonary, hepatic, and renal failure and cannot tolerate surgery;
- 3. Patients suffering from other malignant tumors or a history of other malignant tumors within 5 years; except effectively controlled skin basal cell carcinoma, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary thyroid carcinoma, superficial bladder tumor, etc.;
- 4. Patients requiring long-term use of strong CYP3A4 inhibitors or strong inducers within 7 days before the first administration or during the expected test period;
- 5. Patients who are receiving medications that are known to prolong the QTc interval or may cause torsade de pointes ventricular tachycardia, and who need to continue to receive these medications during the study period;
- 6. History of interstitial lung disease (ILD), or drug-induced interstitial lung disease;
- 7. Severe gastrointestinal dysfunction, diseases or clinical conditions that may affect the intake, transport or absorption of the study drug, such as inability to take the drug orally, uncontrollable nausea and vomiting, history of extensive gastrointestinal resection, uncured recurrent diarrhea, atrophic gastritis (onset age less than 60 years old), uncured gastric diseases requiring proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, raneprazole, etc.) , Crohn's disease, ulcerative colitis, etc.;
- 8. Cardiovascular diseases which meet any of the following: (1) In the resting state, the QTc interval of ECG is >470 msec; (2) Severe abnormalities in heart rhythm, cardiac conduction, and resting ECG, such as complete left bundle branch block, third degree heart block, second degree heart block, PR interval> 250 msec, etc.; (3) Any factors that may increase the risk of QTc interval prolongation or the risk of arrhythmia events, such as heart failure, hypokalemia, hypomagnesemia, etc., congenital long QT syndrome, family history of long QT syndrome, Sudden death unexplained in first-degree relatives under 40 years of age or use of any drug combination that is known to prolong the QTc interval and cause torsion de pointes tachycardia; (4) Left ventricular ejection fraction (LVEF) <50%; (5) Having a history of myocardial infarction, severe or unstable angina, or coronary artery bypass surgery in the last 6 months, or cardiac insufficiency grade ≥ NYHA grade 2; (6) Uncontrollable hypertension (systolic blood pressure ≥150mmHg and/or diastolic blood pressure ≥100mmHg);
- 9. Active period of infectious diseases, such as hepatitis B, hepatitis C and human immunodeficiency virus (HIV) infections;
- 10. Women who are pregnant or breastfeeding, or have fertility but have not taken contraceptive measures;
- 11. People who suffer from uncontrollable neurological or mental illnesses or mental disorders, having poor compliance, cannot cooperate or describe treatment responses;
- 12. Participants in other clinical trials at the same time or expect to receive other anti-tumor treatments outside of this study during the trial period;
- 13. Other situations that researchers think are not suitable for participating in this research.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: EGFR-TKI Treatment Arm
After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of Furmonertinib on the day of baseline follow-up.
Patients in the treatment group should take Furmonertinib (80 mg each time) orally on an empty stomach before breakfast once a day.
The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing.
Patients should maintain oral administration of Furmonertinib for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
|
AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist.
It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs.
Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
다른 이름들:
|
|
위약 비교기: Control Arm
After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of placebo on the day of baseline follow-up.
Patients in the treatment group should take placebo (80 mg each time) orally on an empty stomach before breakfast once a day.
The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing.
Patients should maintain oral administration of placebo for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
|
The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response rate of EGFR-TKI
기간: 6 months
|
defined in this study as the ratio of patients with reduced diameter of any residual lesions on CT scans to the entire patient cohort according to the Independent Review Committee (IRC) image evaluation follow-up.
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lesion-oriented EGFR-TKI response rate
기간: 6 months
|
Defined as the ratio of lesions showing any reduction in diameter on the CT scan to the number of lesions in the entire cohort according to the Independent Review Committee (IRC) image evaluation during follow-up.
|
6 months
|
|
Objective response rate (ORR)
기간: 6 months
|
ORR is evaluated after 6 months of treatment, defined according to the RECIST1.1 standard
|
6 months
|
|
Response rate by Investigators' assessment
기간: 6 months
|
compared with the primary endpoint of Independent Review Committee (IRC) image evaluation
|
6 months
|
|
Second operations
기간: 6 months
|
Number of subjects who had a second resection of residual lesions due to progress of lesions during follow-up.
|
6 months
|
|
Treatment-related adverse events
기간: 6 months
|
the number and grades of treatment-related adverse events in each arm (grading according to CTCAE 5.0)
|
6 months
|
공동 작업자 및 조사자
스폰서
협력자
수사관
- 수석 연구원: Hecheng Li, PhD, MD, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- RTS-015
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .